Phentermine News and Research

RSS
Phentermine is a drug that decreases your appetite.
TOS, OAC call on FDA to address urgent need for obesity treatments

TOS, OAC call on FDA to address urgent need for obesity treatments

VIVUS receives FDA CRL for QNEXA NDA

VIVUS receives FDA CRL for QNEXA NDA

Weight loss pill off shelves due to heart attack risk

Weight loss pill off shelves due to heart attack risk

VIVUS announces QNEXA study results for obesity treatment

VIVUS announces QNEXA study results for obesity treatment

VIVUS second-quarter total revenue decreases to $3.9 million

VIVUS second-quarter total revenue decreases to $3.9 million

Lannett's ANDA for Phentermine Hydrochloride Blue/White Seed Capsules receives FDA approval

Lannett's ANDA for Phentermine Hydrochloride Blue/White Seed Capsules receives FDA approval

VIVUS to present data on Qnexa at ENDO meeting

VIVUS to present data on Qnexa at ENDO meeting

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

Phase 2 study results of Qnexa in patients with OSA presented at SLEEP 2010

VIVUS granted three additional patents for Qnexa

VIVUS granted three additional patents for Qnexa

FDA accepts for filing VIVUS' Qnexa NDA

FDA accepts for filing VIVUS' Qnexa NDA

Missing prescription drugs: Cardinal Health Pharmacy Services to pay $1M penalty

Missing prescription drugs: Cardinal Health Pharmacy Services to pay $1M penalty

Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced

Positive results from phase 2 study evaluating the safety and efficacy of Qnexa announced

FREEDRUGCARD.US launches new Rx savings program to reduce prescription drug prices

FREEDRUGCARD.US launches new Rx savings program to reduce prescription drug prices

VIVUS submits a NDA to the FDA for obesity drug Qnexa

VIVUS submits a NDA to the FDA for obesity drug Qnexa

VIVUS presents additional data on Qnexa Phase 3 trials

VIVUS presents additional data on Qnexa Phase 3 trials

VIVUS to present data on Qnexa at The Obesity Society meeting

VIVUS to present data on Qnexa at The Obesity Society meeting

VIVUS' Phase 3 studies find Qnexa effective in tackling obesity

VIVUS' Phase 3 studies find Qnexa effective in tackling obesity

Fat-fighting drugs may be a far riskier business than they seem

Fat-fighting drugs may be a far riskier business than they seem